Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine

被引:93
作者
Fang, J [1 ]
Coutts, RT [1 ]
McKenna, KF [1 ]
Baker, GB [1 ]
机构
[1] Univ Alberta, Dept Psychiat, Neurochem Res Unit, Edmonton, AB T6G 2R7, Canada
基金
英国医学研究理事会;
关键词
clozapine; cytochrome P450; flavin-containing monooxygenase; human liver; drug metabolism;
D O I
10.1007/PL00005298
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The atypical antipsychotic clozapine has been reported to be metabolised mainly to its N-oxide and N-demethylated products. Tn the present study, individual recombinant cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) enzymes were used to elucidate which enzymes are responsible for these metabolic conversions. In vitro metabolism of clozapine was investigated using human CYP1A1, CYP1A2, CYP2C8, CYP2EI, CYP2C9-arg(144), CYP2C9-cys(144), CYP2C19, CYP2D6, CYP3A4, CYP3A5 and FMO3 supplemented with an NADPH generating system. Clozapine and its N-oxidation and N-demethylation metabolites were determined by an HPLC method with a Hypersil CN column and a UV detector. Of the enzymes investigated, CYP1A2, CYP3A4, CYP2D6, CYP2C8, CYP2C19 and, to a lesser extent, CYP2C9-cys, CYP2C9-arg and CYP3A5 were apparently involved in N-demethylation, while CYP1A2, CYP3A4, FMO3 and, to a lesser extent, CYP2C8, CYP2C19 and CYP3A5 were found to catalyse the formation of clozapine N-oxide. A bank of 16 human liver microsome preparations was investigated for ability to catalyze the production of clozapine N-oxide and N-desmethylclozapine. Attempts were made to correlate the rates of formation of these metabolites of clozapine to previously determined catalytic activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. At a clozapine concentration of 20 mu M, the rate of formation of clozapine N-oxide showed significant correlations with activities of CYP3A4 (P<0.01) and CYP1A2 (P<0.05). The formation of N-desmethylclozapine exhibited significant correlations with CYP1A2 (P<0.01) and CYP3A4 (P<0.01). Similar correlations were observed when the clozapine concentration was increased to 300 mu M except that the formation of clozapine N-oxide no longer correlated with CYP1A2 activity. It can be seen from these results that although some recombinant enzymes individually are capable of metabolising clozapine, the activities of several of these enzymes did not correlate with clozapine metabolism when mixtures of the enzymes are used. By combining the results of the current study and those reported in the literature, it is proposed that CYP3A4 and FMO3 are primarily responsible for the production of clozapine N-oxide, and CYP3A4 and CYP1A2 are primarily responsible for the formation of N-desmethylclozapine. The present study demonstrates the importance of the use of multiple techniques for the elucidation of the enzymes involved in the metabolism of certain drugs.
引用
收藏
页码:592 / 599
页数:8
相关论文
共 32 条
  • [1] CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES
    ALVIR, JMJ
    LIEBERMAN, JA
    SAFFERMAN, AZ
    SCHWIMMER, JL
    SCHAAF, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) : 162 - 167
  • [2] CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST
    BERTILSSON, L
    CARRILLO, JA
    DAHL, ML
    LLERENA, A
    ALM, C
    BONDESSON, U
    LINDSTROM, L
    DELARUBIA, IR
    RAMOS, S
    BENITEZ, J
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) : 471 - 473
  • [3] CENTORRINO F, 1994, AM J PSYCHIAT, V151, P123
  • [4] CLINICAL PHARMACOKINETICS OF CLOZAPINE IN CHRONIC-SCHIZOPHRENIC PATIENTS
    CHENG, YF
    LUNDBERG, T
    BONDESSON, U
    LINDSTROM, L
    GABRIELSSON, J
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (05) : 445 - 449
  • [5] SINGLE-DOSE VS MULTIPLE-DOSE PHARMACOKINETICS OF CLOZAPINE IN PSYCHIATRIC-PATIENTS
    CHOC, MG
    HSUAN, F
    HONIGFELD, G
    ROBINSON, WT
    ERESHEFSKY, L
    CRISMON, ML
    SAKLAD, SR
    HIRSCHOWITZ, J
    WAGNER, R
    [J]. PHARMACEUTICAL RESEARCH, 1990, 7 (04) : 347 - 351
  • [6] MULTIPLE-DOSE PHARMACOKINETICS OF CLOZAPINE IN PATIENTS
    CHOC, MG
    LEHR, RG
    HSUAN, F
    HONIGFELD, G
    SMITH, HT
    BORISON, R
    VOLAVKA, J
    [J]. PHARMACEUTICAL RESEARCH, 1987, 4 (05) : 402 - 405
  • [7] DISPOSITION OF CLOZAPINE IN MAN - LACK OF ASSOCIATION WITH DEBRISOQUINE AND S-MEPHENYTOIN HYDROXYLATION POLYMORPHISMS
    DAHL, ML
    LLERENA, A
    BONDESSON, U
    LINDSTROM, L
    BERTILSSON, L
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (01) : 71 - 74
  • [8] Dain JG, 1997, DRUG METAB DISPOS, V25, P603
  • [9] Ereshefsky L, 1996, J CLIN PSYCHIAT, V57, P12
  • [10] FISCHER V, 1991, MOL PHARMACOL, V40, P846